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Abstract
Idiopathic thrombocytopenic purpura (ITP) is typically a diagnosis of exclusion, assigned by 
clinicians after ruling out other identifiable etiologies. Since a report by Gasbarrini et al. in 1998, 
an accumulating body of evidence has proposed a pathophysiological link between ITP and 
chronic Helicobacter pylori (H. pylori) infection. Clinical reports have described a spontaneous 
resolution of ITP symptoms in about 50% of chronic ITP patients following empirical treatment of 
H. pylori infection, but response appears to be geography dependent. Studies have also 
documented that ITP patients in East Asian countries are more likely to express positive antibody 
titers against H. pylori-specific cytotoxic-associated gene A (CagA), a virulence factor that is 
associated with an increased risk for gastric diseases including carcinoma. While a definitive 
mechanism by which H. pylori may induce thrombocytopenia remains elusive, proposed pathways 
include molecular mimicry of CagA by host autoantibodies against platelet surface glycoproteins, 
as well as perturbations in the phagocytic activity of monocytes. Traditional treatments of ITP 
have been largely empirical, involving the use of immunosuppressive agents and immunoglobulin 
therapy. However, based on the findings of clinical reports emerging over the past 20 years, health 
organizations around the world increasingly suggest the detection and eradication of H. pylori as a 
treatment for ITP. Elucidating the exact molecular mechanisms of platelet activation in H. pylori-
positive ITP patients, while considering biogeographical differences in response rates, could offer 
insight into how best to use clinical H. pylori eradication to treat ITP, but will require well-
designed studies to confirm the suggested causative relationship between bacterial infection and 
an autoimmune disease state.
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Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped, flagellated, 
microaerophilic bacillus that colonizes the gastric mucosa and is likely transmitted via the 
fecal–oral, or oral–oral route during childhood [1–6]. Prevalent in more than half of the 
world’s population, H. pylori infection occurs more frequently in developing nations [1,3]. 
There are documented differences in virulence factors between Western and East Asian 
strains of H. pylori, with the Eastern Asian strains suspected to have higher pathogenicity in 
relation to gastritis and gastric carcinoma [7,8]. Helicobacter pylori is recognized as a 
causative agent for a variety of gastric diseases, including gastritis, peptic ulcer, and gastric 
atrophy, and is correlated with an increased risk for gastric cancer [9]. The bacterium has 
also been linked to a number of extragastric diseases including nutritional deficiencies, such 
as vitamin B12 deficiency, and hematological pathologies, such as idiopathic 
thrombocytopenic purpura (idiopathic immune-mediated thrombocytopenia, ITP) [10,11]. In 
this review, the “virulence” of a particular H. pylori strain will refer to the susceptibility of 
infected individuals to any of the above-mentioned diseases, as well as the severity of 
disease symptoms and associated pathophysiological changes.
ITP is an autoimmune disorder wherein platelets are opsonized by platelet-specific IgG 
autoantibodies (autoAbs), resulting in platelet destruction within the reticuloendothelial 
system [12,13]. Platelets are circulating anucelate cells derived from megakaryocytes within 
the bone marrow. In an adult human, there are approximately 100 billion new platelets 
produced each day with a life span of 8–10 days, which maintains a normal platelet count of 
150–400 × 109 platelets per liter of blood [14,15]. Platelets are known to play a critical role 
in both hemostasis and inflammation [16]. The autodestruction of platelets can be a result of 
infectious, genetic, or environmental factors, with primary ITP having no identifiable 
underlying etiology and secondary ITP having a causative agent positively identified.
Previous reports have postulated various mechanisms for H. pylori’s role in ITP including 
molecular mimicry, increased plasmacytoid dendritic cell numbers, and variable host 
immune response to virulence factors, including vacuolating-associated cytotoxin gene A 
(VacA), and cytotoxin-associated gene A (CagA) – a virulence factor that H. pylori injects 
into host gastric epithelial cells (ECs) via type a IV secretion system [17–20]. The presence 
of anti-CagA antibodies (Abs) has been shown to be predictive of platelet recovery in ITP 
patients treated for the eradication of H. pylori infection [19], which suggests that anti-CagA 
Ab titers can be used as a marker to determine whether eradication of H. pylori may be 
indicated in certain ITP patients. Additionally, molecular mimicry between CagA and 
platelet- associated IgG (PAIgG) has been previously documented [21]. These findings 
suggest that the host Ab response to CagA exhibits cross-reactivity with platelet surface 
antigens (Ags), promoting both platelet aggregation via immune complex formation and 
increased platelet clearance rates, resulting in thrombocytopenia.
Validating the ostensible etiological link between H. pylori infection and ITP could have a 
major impact on the clinical diagnosis and treatment of ITP. Current guidelines in multiple 
countries – including North America, Canada, and a number of countries in Asia – 
recommend H. pylori eradication in ITP patients that fail to respond to traditional 
treatments, if they test positive for the bacterium or reside in highly endemic areas.
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Immune Thrombocytopenic Purpura
ITP is an autoimmune-mediated hematological disorder characterized by the destruction of 
host platelets and the impairment of megakaryocyte platelet production within the bone 
marrow [22]. The diagnosis of ITP relies upon a platelet count of <100 × 109 platelets per 
liter of blood and can be categorized as acute (diagnosis to 3 months), persistent (3–12 
months), or chronic (>12 months) [23]. ITP can be a primary disease or secondary to a 
variety of etiologies including infection, autoimmune, or neoplastic disease. A chronic 
inflammatory state following primary bacterial or viral infection can induce the host 
autoimmune response via multiple mechanisms, including the production of auto-Abs and 
immune complex formation. ITP has an incidence of about 2.7 per 100,000 persons in adults 
and 5 per 100,000 persons in children, with a female sex predilection of 1.7 (female: male 
ratio) [24]. While ITP is typically an incidental finding during routine hematological 
evaluation, the most common clinical presentation of ITP is mucocutaneous bleeding, with 
rare complications of life-threatening hemorrhages [24,25]. ITP has a more acute onset, is 
self-limited, and usually follows an infectious illness in children, while ITP is usually 
chronic with an insidious onset in adults [25–27].
ITP is a diagnosis of exclusion, where the underlying etiology of the thrombocytopenia is 
undetermined. Recent reviews of previously published clinical studies have shown that 
eradication of H. pylori infection in patients with chronic ITP (cITP) results in increased 
platelet counts in about half of the cases [24,28–31]. In the majority of these retrospective 
studies, this associative link is defined as a durable platelet response after H. pylori 
eradication. A 2009 systematic review and meta-analysis revealed a correlation between H. 
pylori infection and ITP with a positive effect of H. pylori eradication on platelet count [29]. 
A current review of the clinical literature confirms that eradication treatment in H. pylori-
positive adult ITP patients resulted in about a 50% complete response rate (Table 1), 
although this is variable by geographic location and many of the studies did not differentiate 
between acute and chronic ITP. Despite mounting evidence suggesting that H. pylori 
infection may also play an etiological role in pediatric cITP, published studies are 
inconclusive and empirical treatment of H. pylori in children with ITP remains controversial 
[32,33]. Due to the scarcity of controlled clinical studies to date and some reports presenting 
conflicting evidence, further research must be performed to confirm H. pylori as a causative 
agent of cITP in both adults and children [24,30,34,35].
Proposed Mechanistic Pathways of ITP Induction
Different strains of H. pylori express a distinct range of virulence factors, resulting in 
increased pathogenesis (increased pathological changes in tissue histology and increased 
local inflammation). Notably, H. pylori strains that are positive (cagA+) for the cytotoxin-
associated gene pathogenicity island (cag PAI) are more virulent than cag PAI-negative 
strains (cagA−) and have been strongly associated with gastric carcinoma [7]. The cag PAI 
encodes a type IV secretion mechanism, giving rise to inflammation via NF-kB activation 
[36,37] and interleukin 8 (IL-8) production [38] and mediates translocation of the 145-kDa 
cagA gene product, CagA, into gastric epithelial cells (ECs) (Fig. 1). Once injected, CagA 
undergoes intracellular tyrosine phosphorylation (pY) and perturbs host cell signaling, 
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promoting disturbance of ECs and gastric carcinogenesis [7,39,40]. While incompletely 
understood, tyrosine phosphorylation of CagA by the Src family protein tyrosine kinase 
mediates a growth-factor-like morphological change in infected gastric ECs known as the 
“humming-bird” phenotype, which is characterized by needlelike cellular protrusions [41–
43]. This change in EC morphology can lead to increased cellular proliferation and has been 
used by researchers to explain the carcinogenic effect of H. pylori infection [44]. The 
severity of the “hummingbird” morphological change depends on the virulence of a given H. 
pylori strain and is a plausible indication of a strain’s potential to induce ITP in infected 
subjects. CagA is noted for the diversity of its amino acid sequence among different H. 
pylori strains, and published reports have revealed differences in infection severity between 
Western and Eastern Asian strains of H. pylori, with the extent to which a given strain’s 
CagA undergoes intracellular pY serving as a strong indicator of virulence [41].
Various mechanisms have been proposed for the induction of ITP as a result of H. pylori 
infection, incorporating both the innate (T-cell lymphocytes, neutrophils, monocytes, and 
cytokines) and acquired (B-cell lymphocytes) immune system. These include (1) the 
production of Ag-specific Abs that cross-react with platelet surface glycoproteins [21], (2) 
genetic differences in HLA class II allele patterns [45], (3) enhanced platelet activation from 
the interaction of H. pylori-bound von Willebrand factor (VWF) interacting with platelet 
surface Ag (GPIb) with subsequent aggregation supported by IgG [46], (4) the induction of 
the B-cell-mediated expansion of platelet-reactive Abs [47,48], (5) enhanced platelet 
activation from the binding of vacuolating cytotoxin (VacA) virulence factor to multimerin 
1 on platelets [20], and (6) the downregulation of FcγRIIB receptors on monocytes, resulting 
in increased phagocytic activity, by H. pylori infection [49]. Helicobacter pylori Ags are 
currently known to induce a T- and B-cell-mediated response, which results in host 
production of H. pylori-specific Abs [50,51]. A recent study evaluated cytokine levels in 
patients with chronic ITP before and 6 months after H. pylori eradication. Antibiotic 
treatment, in patients with a positive platelet response to H. pylori eradication, resulted in a 
reduction in the cytokine profile consisted with Th1 and Th17 cells; also, there was an 
enhancement of a Th2 cytokine profile, as well as an increased number of T regulatory cells 
[52]. Some of the Abs generated during this immune response demonstrate cross-reactivity 
with host cells, including gastric and duodenal ECs, renal tubular cells, and salivary gland 
cells [53]. Recent clinical studies have elucidated an association between cagA+ H. pylori 
and ITP [17–19,21]. Takahashi et al. [54] demonstrated that patients with ITP had PAIgGs 
that cross-reacted with H. pylori-specific CagA, and reported a decline in anti-CagA Abs, as 
well as an increase in total circulating platelet count, in patients who underwent successful 
H. pylori eradication treatment. These findings parallel those of Kodama et al. [19], who 
also reported that H. pylori eradication therapy improved platelet counts in H. pylori-
positive ITP patients and led to a significant decrease in anti-CagA Abs. One explanation for 
this finding is the possibility of molecular mimicry between CagA Ags and platelet surface 
glycoproteins, resulting in the anti-CagA Ab targeting of host platelets (Fig. 2). Although no 
research published to date has definitively established CagA as a causative factor in ITP, 
retrospective clinical studies substantiate a correlation of H. pylori-specific CagA with 
clinical ITP [55].
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Injection of CagA into gastric epithelial cells results in a number of intracellular changes, 
morphological changes, and transcriptional activation (Fig. 1). A prospective clinical study 
performed by Asahi et al. [49], showed that H. pylori infection was correlated with an 
increase in monocyte phagocytic activity and a downregulation in FcγRIIB receptor 
expression on monocytes. Eradication treatment resulted in the resolution of these 
abnormalities as well as a decrease in circulating anti-CagA Abs. These findings suggest 
that the mechanism through which H. pylori induces an autoimmune disease state may very 
well be multifactorial: platelet clearance by macrophages in the reticular endothelial system, 
suppression of antigen presentation by macrophages, inhibition of lymphocyte responses to 
platelet surface antigens, direct increases in platelet activation, and cross-reactivity of 
autoplatelet Abs. A previous study exploring the pro-inflammatory activation of neutrophils 
and monocytes by H. pylori was not associated with the cagA or vacA genotype [56]. The 
lack of controlled scientific studies and the lack of establishment of Koch’s postulate require 
additional research to be performed to confirm a definitive mechanistic pathway linking H. 
pylori infection and ITP.
The Role of Biogeography
Computational phylogeography of H. pylori indicates a trend of spreading, alongside 
populations of its human host, from east Africa as early as 63,000 years ago [57]. The 
findings of Linz et al. demonstrate that the biogeographical evolution of modern H. pylori 
strains has been marked by high mutation rates and frequent interstrain recombination 
[58,59]. Helicobacter pylori strains present today subdivide into biogeographic populations 
that appear to reflect human migration patterns [60–62]. A comparison of 38 representative 
isolates of complete cag PAI genomes from known biogeographic islands was performed, 
showing that cagA gene content is highly conserved and its genetic diversity is reflective of 
geographic location [63]. The cag PAI is present in 95% of strains assigned to hpAfrica1, 
hpEastAsia, and hpAsia2 populations, while no hpAfrica2 strains possess the island, and cag 
PAI is variably found in hpEurope, hpNEAfrica, hpSahul, and the hspAmerind 
subpopulation of hpEastAsia (Fig. 3A) [63].
There is evidence for differences in infection severity between Western and Eastern Asian 
H. pylori strains. Eastern Asian H. pylori strains have been documented as more pathogenic, 
correlating with an increased occurrence of gastric carcinoma (among other GI pathologies) 
in H. pylori-positive patients in East Asia (including the countries of Japan, Korea, China, 
and Russia) [41,64]. This observed increase in pathogenicity correlates with an increase in 
CagA phosphosite abundance [7]. Furthermore, increased CagA pY can induce greater 
pathologic morphology changes in host gastric ECs [7]. CagA proteins of most Western H. 
pylori isolates have a 34-amino acid sequence that variably repeats among different strains 
[7]. This repeating sequence contains a conserved Glu-Pro-Ile-Tyr-Ala (EPIYA) sequence, 
which encodes the site for tyrosine phosphorylation (pY) [7]. CagA proteins having multiple 
EPIYA motifs undergo more extensive pY, exhibit increased specific binding to SHP-2 
phosphatase, and induce greater morphological changes (“hummingbird phenotype”) in 
gastric ECs accompanied by sustained ERK activation, altered cellular migration 
(scattering), and induced apoptosis [65–67]. CagA proteins from Eastern Asian strains of H. 
pylori have distinct pY sequences at the region corresponding to the repeat sequence of 
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Western CagA [7] (Fig. 4). These findings suggest that the CagA pY state underlies H. 
pylori’s pathologic effect in a range of diseases, including gastritis, gastric carcinoma, and 
ITP [41,68].
In East Asia, CagA seropositivity is reported to be higher in patients diagnosed with gastric 
cancer than in those with gastritis alone [69], suggesting that anti-cagA Abs may be used as 
a biomarker for gastric cancer in East Asian countries [70]. Most H. pylori infections in 
Japan are positive for East Asian-type cagA [71,72]. However, in southwestern regions of 
Japan such as Okinawa, where the incidence of gastric cancer is lower, there are markedly 
lower rates of East Asian-type CagA. It has been postulated that the horizontal transmission 
of Western H. pylori strains to Japanese natives may have occurred during post-WWII 
occupation of Okinawa by US citizens [64,73]. Although the isoform of CagA found in 
southwestern Japan (“J-Western” CagA) differs from Western-type CagA via a 12-bp 
insertion in the cagA gene, the similarity between CagA multimerization sequence in 
Okinawan and Amerindal strains suggests they share ancestral lines [64,70,74]. The 
presence of both Western and East Asian-type CagA within Japan, along with 
correspondingly decreased incidence of gastric cancer among Japanese natives who test 
positive for only Western- or J-Western-type CagA, supports previous findings that 
variation in the virulence of CagA is important in the pathogenicity of H. pylori infection. 
Although few studies have probed the link between CagA virulence and ITP as 
comprehensively as gastric cancer, it is conceivable that similar trends underlie the increased 
prevalence of cITP in patients with cagA+ H. pylori infections.
Vacuolating cytotoxin (VacA) virulence factor has also been proposed as a factor in the 
development of ITP, via the binding to multimerin 1 on platelets leading to platelet 
activation [20]. Although not as thoroughly explored as that of CagA, the VacA genome 
may also be a variant that is based on bacterial and host migratory patterns. Lu et al. [75], 
performed a full genome comparative analysis of an H. pylori isolate in Australia, Sahul 64. 
This study suggested that Sahul 64, which was found to lack the cagPAI, have highly 
divergent cell envelope proteins, encode no transportable VacA protein, and might be better 
adapted to cause endogenous infections in Australians, despite the fact that these infections 
were less virulent compared to other cagPAI-positive strains. Evaluation of polymorphisms 
in virulence factors, CagA and VacA, in patients from different countries showed that the 
presence of the cagA gene correlated with vacA signal sequence s1/ m1 or s1/m2, and cagA-
negative samples correlated with type s2/m2, suggesting that vacA genetic variation may be 
correlated to cagA biogeographical variation. Additionally, in the French study, cagA was 
positively correlated with the presence of the s1/m1 vacA genotype as well as with the 
induction of interleukin-8 (IL-8) [76–78]. Due to limited studies published on the genetic 
phylogeny of vacA, further investigation into the biogeography of this virulence factor in 
relationship to ITP may offer greater clinical insight.
In addition to bacterial biogeography, a patient’s biogeography may also play a role in the 
etiology of H. pylori-induced ITP. For example, monocyte FcγR receptor expression can be 
influenced by both environmental factors, such as infection, and genetic factors, such as 
polymorphisms [49]. An alteration in the expression of the FcγR gene can result in a change 
in a monocyte’s affinity for binding IgG, which can cause a change in the clearance rate of 
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immune complexes [79]. Changes in receptor expression, such as the presence of single 
nuclear polymorphisms in the FcγRIIB gene or its promoter region, can change 
transcriptional activity and has been shown to be predictive of the development of chronic 
disease in children presenting acute ITP [80–83]. Studies evaluating these genetic changes in 
receptors have not evaluated cases of H. pylori-positive, eradication-responsive ITP. We 
hypothesize that the migratory patterns, genetic profiles, and biogeography of both patient 
and pathogen, H. pylori, are likely to play a role in the induction of an autoimmune disease 
state. The scarcity of published literature to date warrants further exploration on the genetic 
makeup of both the patient and the infecting H. pylori strains in relation to ITP.
Current Policies/Recommendations for Helicobacter pylori Eradication
Although the molecular basis for the association between ITP and H. pylori infection has not 
been conclusively established, various health organizations around the world currently 
advocate for the detection and eradication of H. pylori infection in the face of ITP. In 1987, 
the European Helicobacter Study Group (EHSG) was founded to promote multidisciplinary 
research centered on H. pylori-associated pathologies. The EHSG convenes consensus 
meetings on a regular basis to recommend when and how to treat patients infected with H. 
pylori. In 2010, 44 experts from 24 countries participated in the Maastricht IV/Florence 
Consensus Report and concluded that ITP is one of the extragastric diseases for which the 
detection and eradication of H. pylori infection is indicated [84]. While more conservative, 
current guidelines (2011) from the American Society of Hematology acknowledge H. pylori 
as a potential etiology for ITP and recommend that more extensive testing for infection be 
reserved for patients who either reside in highly endemic regions, or exhibit symptoms 
beyond thrombocytopenia (+/− anemia with concurrent bleeding) [26].
In 2009, the Asia-Pacific Conference convened to review the most current information on H. 
pylori management to synthesize new guidelines for the indication of its treatment and 
eradication and concluded that H. pylori eradication in infected patients with ITP was 
indicated [85]. The Japanese Society for Helicobacter Research considers H. pylori infection 
to be an indication for eradication therapy for four diseases: peptic ulcer, gastric MALT 
lymphoma, early gastric cancer, and ITP [85,86]. Because of the high prevalence of H. 
pylori infection in Japan, in addition to the increased pathogenicity of the endemic strains 
and subsequent risk of gastric cancer with long-term infection, eradication treatment has 
been approved by the Japanese health insurance system as a result of the recommendations 
from the Japanese Society for Helicobacter Research [70]. Other East Asian countries, 
including Korea, have also adopted H. pylori eradication guidelines for the treatment of both 
gastric and extragastric diseases (e.g., cITP) [87]. The findings of some reports suggest that 
ITP disease duration, along with the pathogenicity of infecting H. pylori strain (primarily the 
likelihood that a patient will be seropositive for CagA-specific autoAbs), is the chief 
predictor of patient platelet response following H. pylori eradication treatment, but more 
controlled clinical studies are required to confirm the biogeographical link between H. pylori 
strain and the likelihood of a positive platelet response (Fig. 3B, Table 1).
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Clinical Relevance
A principle concern for individuals with ITP is life-threatening hemorrhage. A study of 117 
adult cases of cITP revealed that 33% of treated adults achieved stable remission, with the 
incidence of hemorrhagic complications being more common in patients greater than 60 
years of age (10.4%) than in patients younger than 40 years (0.4%) [88]. A case series 
review including 1817 patients with ITP revealed that the risk of fatal hemorrhage, before 
age adjustment, was 0.0162–0.0389 cases per patient-year [89]. Intracranial hemorrhage is 
the most life-threatening complication in patients with severe thrombocytopenia, with a 
mortality rate up to 5% in adults with cITP [90,91]. Thirty percent of pediatric patients will 
have a prolonged course and 5–10% will develop chronic severe refractory disease [92,93], 
with a 0.1–0.5% risk of intracranial hemorrhage, usually with platelet counts lower than 10 
× 109/L [94]. Treatment for ITP is recommended for patients with a platelet count below 50 
× 109/L, bleeding due to platelet dysfunction, the presence of other hemostatic defects, 
surgery, trauma, or other identified comorbidities [55].
Current treatment for ITP in the United States involves the use of immunosuppressive 
agents, such as corticosteroids, intravenous immunoglobulin therapy (IVIg), anti-D 
immunoglobulin (anti-D), Rituximab, or salvage splenectomy, all of which can be expensive 
and have associated risks and adverse effects [26]. About 20% of patients do not sustain a 
normal platelet count after medical therapy or splenectomy, and 10–20% of responders to 
splenectomy will relapse [55]. In a 2009 meta-analysis conducted by Stasi et al., positive 
platelet responses were found in roughly 50% of adult ITP patients after H. pylori 
eradication treatment, with more significant platelet count increases observed in less severe 
cases of ITP. As most of the studies included in the meta-analysis by Stasi et al. [29] 
considered H. pylori eradication in primarily severe cases of ITP, absolute patient response 
rates to bacterial eradication treatment may exceed 50% efficacy. In patients that respond to 
H. pylori eradication therapy, autoplatelet Ab responses are completely resolved, without 
relapse for over 7 years [95]. However, platelet response to H. pylori eradication for the 
treatment of ITP appears to correlate with geographic location: higher response rates are 
observed in Japan and Italy (ranging from 28 to 100%) than in the United States and other 
European countries (<13%) [95]. A study from Iran reported that H. pylori eradication led to 
increased platelet count in those with mild ITP (platelet count >50 × 103 μL), but was less 
successful in patients with severe ITP (platelet count <50 × 103 μL) [96]. Meanwhile, 
eradication of infection in H. pylori-positive children and adolescent ITP patients in Brazil 
had a response rate of 60% compared to untreated, infected patients, 18.2% [97]. Taken in 
aggregate, these clinical observations underscore the importance of patient biogeography as 
a predictor of response to H. pylori treatment and further implicate regional H. pylori strain 
variation.
Active H. pylori infections are diagnosed using the 13C-urea breath test, detecting bacterial 
Ag in the stool, with bacterial culture or PCR via gastric biopsy, or silver staining of gastric 
tissue for visualization of H. pylori. Additionally, ELISA-based serum Ab testing may be 
performed, but may be insensitive, not necessarily indicative of active bacterial infection, 
and may be falsely positive after IVIg therapy. The currently recommended treatment 
regimen for H. pylori infection consists of a combination of antibiotic therapies, which 
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usually poses significantly less adverse effects and less overall costs than most ITP 
treatments. Historically, recommended eradication treatment has been a triple therapy 
cocktail, consisting of a proton-pump inhibitor, amoxicillin, and clarithromycin or 
metronidazole for up to 2 weeks. The addition of various probiotic compound supplements, 
containing Lactobacillus, Bifidobacterium, Saccharomyces, and other bacteria, have also 
been implicated in both reducing the adverse effects of eradication treatment and improving 
eradication rates, although studies supporting this are contradictory [98]. The antibiotics 
chosen may vary by region due to the emergence of H. pylori antibiotic resistance in highly 
endemic areas [99,100]. This rise in antimicrobial resistance, particularly against 
clarithromycin and metronidazole, combined with poor patient compliance, has resulted in a 
<70% eradiation rate in most countries [101,102]. Resistant H. pylori strains necessitate 
sequential or quadruple therapy (either bismuth-based or nonbismuth-based), and the use of 
rifabutin and levofloxacin as salvage treatments when initial therapy fails [100,102]. 
Although new diagnostic tools are being developed for defining susceptibility profiles for H. 
pylori infections, there is no current “tailored” eradication therapy protocol in effect [102]. 
Taking into account the literature supporting the link between H. pylori infection and ITP, 
H. pylori should be considered as a potential etiology for ITP in both children and adults; 
however, eradication therapy should be reserved for those who test positive for active 
infection.
Conclusions
Literature over the past 20 years has elucidated the potential link between chronic H. pylori 
infection and the development of ITP in both adults and children. Most publications are 
retrospective clinical studies with variable treatment response rates, potentially due to 
biogeography and subsequent genetic variation of the bacteria and/or patient. Many studies 
have proposed that H. pylori virulence factor, CagA, stimulates the development of anti-
CagA antibodies that are cross-reactive with platelet surface antigens, resulting in 
thrombocytopenia. Future studies exploring the potential molecular link between chronic H. 
pylori infection and ITP are justified by the fact that (1) upper gastrointestinal (GI) infection 
by H. pylori is prevalent in over 50% of the world’s human population [1], and because (2) 
clinical studies of ITP to date have remained largely observational in nature, with few 
having substantiated the proposed molecular mechanisms of disease pathogenesis by 
experimental means. Further studies exploring the potential pathophysiological mechanism 
between infectious agents (e.g., H. pylori) and ITP, via the role of genetic variation and 
biogeography, could open a new avenue with regard to the diagnosis and treatment of 
patients with idiopathic hematological disorders. Lack of robust animal models of ITP 
associated with H. pylori infections has hampered mechanistic studies underlying its 
potential relationship with cITP. However, with the recognition that controlled experiments 
are necessary in establishing a causative link, current published literature is substantial 
enough to suggest an associative link between H. pylori and ITP and to warrant empirical 
eradication treatment in patients that test positive for active H. pylori infection or those in 
highly endemic areas, whose populations are infected with CagA-virulent strains.
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Figure 1. 
Effects of Helicobacter pylori CagA virulence factor on host cell. Helicobacter pylori 
injects CagA (red) into a host gastric epithelial cell via a type IV secretion system (T4SS, 
tan). Dimerizatiom of primary receptors activated by T4SS core complex: α5β1 integrin and 
receptor tyrosine kinases (purple). Within ECs, CagA EPIYA motif is recognized by major 
host kinases, Src, and Abl, resulting in tyrosine phosphorylation (yellow). Phosphorylated 
CagA (red and yellow) induces host cell pathology. Both, intracellular CagA and 
phosphorylated CagA, induce major effects on host cell signaling, resulting in changes in 
cell morphology, cell cycle regulation, and pro-inflammatory cytokine transcription. 
Intercellular junctions (gray): AJ, adherens junctions; TJ, tight junctions. This figure is an 
adaptation of Figures 2, 3, and 4 from [103].
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Figure 2. 
Host production of anti-CagA Abs, resulting in ITP. (1) Helicobacter pylori injects CagA 
(red) into host gastric ECs via T4SS (tan). (2) CagA undergoes intracellular phosphorylation 
(red and yellow). (3) Two Ags are produced and presented on the cell surface of the infected 
host cell: one specific for CagA (light blue) and one that shows molecular mimicry to 
platelet surface glycoproteins (purple). (4) Host Abs recognizing either Ag undergo 
replication within the host lymph nodes. (5) These Abs are then released into the circulatory 
system, resulting in a secondary immune-mediated thrombocytopenia. (6) Increased platelet 
clearance is a result of Ab-Ag recognition in the reticuloendothelial system (R.E.S.), 
increased immune complex formation, and decreased platelet production in the bone 
marrow. (pink: platelet; orange: megakaryocyte; blue: mononuclear phagocyte; green: 
R.E.S.)
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Figure 3. 
Distribution of cag PAI in a collection of Helicobacter pylori strains from different world 
populations. Geographic sources of strains whose cag PAI sequences are now available. 
Each dot indicates the source of isolation of one of the 38 cag PAI sequences that were 
analyzed. The dots are color-coded by population or subpopulation as in (A). Representation 
of geographical distribution of platelet response after eradication treatment in H. pylori-
positive adult patients (B). Data extrapolated from Table 1. Gray (0–25% response), yellow 
(25–50% response), green (50–75% response), and red (75–100% response) (modified with 
permission from [63]).
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Figure 4. 
Diversity in CagA tyrosine phosphorylation (pY) sites. Tyrosine phosphorylation of 
cytotoxin-associated antigen A (CagA) by SRC kinase occurs at the EPIYA motif. There are 
four different EPIYA sites, called EPIYA-A, -B, -C, and -D, based on the sequence 
surrounding the EPIYA motif. Western strains of Helicobacter pylori express a form of 
CagA that contains the EPIYA-A and EPIYA-B sites, followed by 1–3 repeats of the 34-
amino acid sequence that contains the EPIYA-C site (red boxes). East Asian strains of H. 
pylori express a form of CagA in which the EPIYA-C site is replaced with the EPIYA-D site 
(yellow box) (reprinted with permission from [41]).
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